Cargando…

Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease

Randomized trials of pulmonary vasodilators in pulmonary hypertension due to left heart disease (Group 2) and lung disease (Group 3) have demonstrated potential for harm. Yet these therapies are commonly used in practice. Little is known of the effects of treatment outside of clinical trials. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gillmeyer, Kari R., Miller, Donald R., Glickman, Mark E., Qian, Shirley X., Klings, Elizabeth S., Maron, Bradley A., Hanlon, Joseph T., Rinne, Seppo T., Wiener, Renda S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020250/ https://www.ncbi.nlm.nih.gov/pubmed/33868640 http://dx.doi.org/10.1177/20458940211001714

Ejemplares similares

Socioeconomically disadvantaged veterans experience treatment delays for pulmonary arterial hypertension
por: Gillmeyer, Kari R., et al.
Publicado: (2022)

Implementation of guideline-based therapy for chronic obstructive pulmonary disease: Differences between men and women veterans
por: Rinne, Seppo T, et al.
Publicado: (2017)

Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity
por: Sangani, Ruchika A., et al.
Publicado: (2022)

Adherence to Follow-up Testing Recommendations in US Veterans Screened for Lung Cancer, 2015-2019
por: Núñez, Eduardo R., et al.
Publicado: (2021)

Factors Associated With Declining Lung Cancer Screening After Discussion With a Physician in a Cohort of US Veterans
por: Núñez, Eduardo R., et al.
Publicado: (2022)

Efficacy and safety of oral pulmonary vasodilators in pulmonary veno‐occlusive disease
por: Nakamura, Junichi, et al.
Publicado: (2022)

Pulmonary vasodilator treatment in pulmonary hypertension due to left heart or lung disease: time for a high-definition picture?
por: Piccari, Lucilla, et al.
Publicado: (2021)

Adenosine as pulmonary vasodilator in ARDS
por: Molina, JM, et al.
Publicado: (1998)

Using a person-centered approach in clinical care for patients with complex chronic conditions: Perspectives from healthcare professionals caring for Veterans with COPD in the U.S. Veterans Health Administration’s Whole Health System of Care
por: Anderson, Ekaterina, et al.
Publicado: (2023)

Pulmonary vasodilator use in continuous-flow left ventricular assist device management
por: Pirlamarla, Preethi, et al.
Publicado: (2021)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
por: Maron, Bradley A., et al.
Publicado: (2022)

Inhaled pulmonary vasodilators in refractory hypoxemia
por: Wright, Brian J.
Publicado: (2015)

Effectiveness of pulmonary vasodilators on pulmonary hypertension associated with POEMS syndrome
por: Ohashi, Kana, et al.
Publicado: (2019)

Pulmonary vasodilation in acute pulmonary embolism – a systematic review
por: Lyhne, Mads Dam, et al.
Publicado: (2020)

Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
por: Chida-Nagai, Ayako, et al.
Publicado: (2020)

Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis
por: Kimuro, Keiji, et al.
Publicado: (2022)

Oxygen-Sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension
por: Morales-Cano, Daniel, et al.
Publicado: (2021)

Oxygen dependence of endothelium-dependent vasodilation: importance in chronic obstructive pulmonary disease
por: Keymel, Stefanie, et al.
Publicado: (2016)

Improvement of pulmonary arterial compliance by pulmonary vasodilator in pulmonary hypertension from combined pulmonary fibrosis and emphysema
por: Kusaka, Kei, et al.
Publicado: (2019)

Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension
por: Becker, Eva Maria, et al.
Publicado: (2013)

Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database
por: Ventetuolo, Corey E., et al.
Publicado: (2017)

It’s Time to Put the Term “Pulmonary Vasodilators” to Rest
por: Rubin, Lewis J.
Publicado: (2021)

Selective Use of Pulmonary Vasodilators in Patients with Fontan Physiology
por: Glenn, Thomas, et al.
Publicado: (2022)

Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis
por: Monfredi, Oliver, et al.
Publicado: (2016)

Pulmonary arterial hypertension due to pulmonary veno-occlusive disease in systemic sclerosis: Importance of early diagnosis and cautious use of pulmonary vasodilator therapy
por: Koito, Hitoshi
Publicado: (2012)

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
por: Muzevich, Katie M, et al.
Publicado: (2014)

When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found
por: Wiener, Renda Soylemez, et al.
Publicado: (2013)

Prescription Patterns for Pulmonary Vasodilators in the Treatment of Pulmonary Hypertension Associated With Chronic Lung Diseases: Insights From a Clinician Survey
por: Thomas, Christopher A., et al.
Publicado: (2021)

Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study
por: Naranjo, Mario, et al.
Publicado: (2023)

Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy
por: May, Adam, et al.
Publicado: (2014)

Endogenously released adenosine causes pulmonary vasodilation during the acute phase of pulmonary embolization in dogs()
por: Takahama, Hiroko, et al.
Publicado: (2019)

Pulmonary Vasodilator Therapy in Children with Single Ventricle Physiology: Effects on Saturation and Pulmonary Arterial Pressure
por: Jeremiasen, Ida, et al.
Publicado: (2020)

Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide
por: Sugawara, Eri, et al.
Publicado: (2017)

Hilar Abnormality in the Left Lung: Left Pulmonary Artery Posterior to the Left Mainstem Bronchus
por: Krylova, Sofia V, et al.
Publicado: (2023)

Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries
por: Jain, Pritesh P, et al.
Publicado: (2014)

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension
por: Cirulis, Meghan M., et al.
Publicado: (2019)

Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
por: Jeremiasen, Ida, et al.
Publicado: (2022)

Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial
por: Andersen, Asger, et al.
Publicado: (2021)

Pulmonary Tumor Thrombotic Microangiopathy with Administration of Pulmonary Vasodilator Resulting in Clinical Improvement Prior to Final Diagnosis
por: Tomioka, Tomoko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fc5cj6oq4mnnofpidj8g3jdkqv